*****
TODAY’S NEWS
It appears that the 3-way bidding war for Ratiopharm is going to be won by Teva. So, who will Pfizer go after next?
Abraxis jumps after successful lung cancer comparative trial – The Abraxis product, Abraxane, combines paclitaxel with a human protein to administer it in higher doses, according to company data. During the trial, in the third of three phases generally required for regulatory approval of a medicine, Abraxane showed a more successful response rate in treating non- small cell lung cancer than paclitaxel…more
Roche bullish on some pipeline drugs for cancer and cholesterol – The chief executive of Roche Holding AG said on Wednesday the Swiss drugmaker’s experimental drugs to treat melanoma and raise “good” HDL cholesterol could transform treatment of cancer and heart disease. In an interview, Roche Chief Executive Officer Severin Schwan said its drug designed to raise good cholesterol, called dalcetrapib, “could be a game changer in how we treat lipid diseases,” noting it is being tested in 15,000 patients in partnership with Japan Tobacco Inc…more
RECOMMENDED
Presentation skills – Your employees need training on more effective presenting. Impactiviti’s vendor/partners have just what you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
Being purpose-full. Can you state your purpose in one minute or less to that person in the mirror?
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
